Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome  by Al-Seraihy, Amal et al.
original research report
Hematol Oncol Stem Cell Ther 4(3)     Third Quarter 2011 hemoncstem.edmgr.com 121
Myelodysplastic syndromes (MDS) are a het-erogeneous group of clonal bone marrow stem cell disorders, characterized by ineffec-
tive erythropoiesis, a variable degree of cytopenia, and 
an increased risk for developing acute myelogenous leu-
kemia (AML). MDS is rare in children (incidence <3- 
4/1 000 000 children.1 Those affected almost always have 
advanced disease (RAEB-I and RAEB-II) and progress 
to leukemia more often than adults.2,3The majority of 
children also have associated chromosomal abnormali-
ties, the most frequent of which is monosomy 7.4 
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BACKGROUND AND OBJECTIVES: allogeneic stem cell transplantation (sCt) offers the best chance of cure 
and long-term survival for children with myelodysplastic syndromes (mDs). 
DESIGN AND SETTING: retrospective analysis of pediatric patients with primary mDs treated with allogeneic 
sCt at a single institution treated between January 1993 and December 2008. 
PATIENTS AND METHODS: of 16 consecutive children who received allogeneic sCt for treatment of mDs in 
our center, 14 patients met the criteria of mDs according Who i and ii criteria. the median age was 4.8 years 
(range, 1-14 years) and 64% were male. the median time from diagnosis to transplant was 6 months. mDs stage 
was refractory cytopenia (rC) in 9, refractory anemia with excess blasts (raEB) in 5. monosomy 7 was present 
in 35% of the patients. the majority of patients (11/14) were conditioned with a busulfan-based myeloablative 
(ma) regimen with addition of low-dose of etoposide (30 mg/kg). all but one received a bone marrow graft. 
RESULTS: nine patients achieved complete remission (Cr), and seven remain alive. at a median follow-up of 3 
years (range, 2-14 years) the os and Efs was 57% (95%Ci, 0.28-0.78). Cumulative Efs at 10 years was 43% (95% 
Ci: 0.14–0.70). relapse-related mortality was 21.4%; nonrelapse mortality (nrm) was 28.57%. all the survivors 
had etoposide in their conditioning regimen. Patients younger than 10 years had better survival (P=.001). 
CONCLUSION: Children with mDs achieve encouraging os and Efs following allogeneic sCt. a busulfan-
based regimen with a lower dose of etoposide is an effective and less toxic regimen. the outcomes are best in 
younger patients.
The MDS classification that includes some of the FAB 
subtypes (juvenile myelomonocytic leukemia [ JMML], 
the monosomy 7 syndrome and others) has not been 
universally accepted and today there is a consensus that 
these disorders are distinct from MDS.5 An international 
consensus has been recently achieved on the classification 
of MDS in childhood. This classification includes refrac-
tory cytopenia (RC) and refractory anemia with excess 
blasts (RAEB).6, 7 Therapy-related MDS are generally 
considered separately, given the different etiology, clinical 
characteristics, and poorer prognosis.8,9 
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The intent of treatment in children with MDS is 
curative whereas in adults palliation is often the most 
feasible approach. Even though spontaneous remissions 
of MDS with monosomy 7 have been reported, these 
are rare and do not preclude initiation of therapy with 
a curative intent.10 Intensive chemotherapy, similar to 
treatment in patients with newly diagnosed AML, can 
induce remissions in 15% to 60% of patients, but these 
remissions are not durable, resulting in high relapse rates 
and overall survival (OS) rates of <30%.11-13Allogeneic 
SCT, using bone marrow (BM) from matched related 
donors (MRD) offers the best chance for cure with long-
term survival.14-16 Alternative donors such as matched 
unrelated donors (MUD), unrelated cord blood (UCB), 
or partially matched related donors are also available op-
tions in the absence of a full-matched donor.17-19 
The paucity of reports on the outcome of SCT for 
MDS in the pediatric literature can be explained by sev-
eral factors, including the rarity of MDS in children, the 
lack of a widely accepted classification, the reporting of 
pediatric populations within adult studies, and report-
ing MDS with other myeloproliferative disorders such 
as JMML, CMML, or therapy related AML (t-AML). 
This study presents the outcome of allogeneic SCT in 
children with MDS who were retrospectively classified 
according to the new WHOII classification for child-
hood MDS.7
PATIENTS AND METHODS
Between January 1993 and December 2008, 16 children 
underwent allo-SCT for treatment of MDS in our cen-
ter. The diagnosis of MDS was based on an evaluation 
of the bone marrow aspirate, bone marrow biopsy, pe-
ripheral blood smear and cytogenetic studies. Fourteen 
patients met the criteria of MDS according WHO I 
and II criteria. Patient characteristics at transplant are 
summarized in Table 1. The median age at SCT was 4.8 
years and disease duration pre-SCT ranged from 2 to 
12 months with a median of 6 months. The majority of 
patients presented with symptoms relating to neutrope-
nia, thrombocytopenia, and anemia. Cytogenetic studies 
were available on all patients, and five had monosomy.7
Treatment prior to transplant consisted of red blood 
cell transfusions in 4 patients, platelet transfusions in 6 
patients and granulocyte-colony stimulating factor (G-
CSF) in 3 patients with RC. Three patients with RAEB 
received AML-type chemotherapy. The three patients 
achieved complete remission (CR-1) prior to SCT.
The source of the stem cells was bone marrow from 
an HLA-matched sibling or parent in 13 patients and 
UCB in one patient. Harvested marrows were not ma-
nipulated, and the median CD34 dose in matched-re-
lated was 6.3×106 per kg recipient body weight (range 
2.3-13× 106).
All patients were conditioned with an myeloabla-
tive regimen. This regimen consisted of intravenous 
(IV) busulfan (BU) at 4 mg/kg daily in four divided 
doses for 4 days (total dose 16 mg/kg), IV cyclophos-
phamide (CY) at 50 mg/kg daily for 4 days (total dose 
200 mg/kg) and IV etoposide (VP-16) at 300 mg/m2 
daily for 3 days (total dose 900 mg/m2). Eleven patients 
received BU/CY/VP16; three patients received BU/
CY only. The choice of conditioning regimen was based 
on current practices within the institution at that time. 
GVHD prophylaxis was with cyclosporine A (CSA) 
and methotrexate in 11 patients, CSA and methylpred-
nisone in one patient and CSA only in two patients.
 All patients were housed in HEPA-filtered rooms 
Table 1. Patient clinical and transplantation characteristics.
  Characteristic Number of patients (unless noted otherwise)
  median age, year  (range)  4.8( 1-14)
  Gender (male/female)                                    9/5
  Time from diagnosis to transplant, 
  months  (range)  6 (3-22)
  mdS Subtype according WHO-ii 9
  refractory cytopenia of childhood
  reab 5
  Cytogenetics
     normal 6
     monosmy 7 5
     Others 3
  Graft
     bone marrow 13
     Cord blood 1
     Cd34/kg 6.28×106 (1.2-13)
  Conditioning
     buS/CYC/VP16 11
     buS/CYC 2
     buS/CYC/aTG    1
  GVHD prophylaxis
     CSa 2
     CSa/mTX 11
     CSa/prednisone 2
raeb: refractory anemia with excess blasts; uCOb: unrelated cord blood; buS: 
busulphan; CYC: cyclophosphamide; aTG: anti-thymocyte globulin; GVHd: graft-versus-
host disease; CSa: cyclosporine; mTX: methotrexate.
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and were isolated until engraftment. Intravenous im-
munoglobulin (IVIG) was administered every 2 weeks 
until day +90. All patients received aciclovir and no 
prophylactic antifungal therapy was given. All blood 
products were leukocyte-filtered and irradiated.
Engraftment was defined as the first of 3 consecutive 
days with an absolute neutrophil count >0.5/L×109/
L. Platelet recovery was defined as a platelet count 
>20×109/L for 7 days without any transfusion. Relapse 
was identified by recurrence of a prior cytogenetic abnor-
mality or by reappearance of morphologic evidence of 
disease. Graft failure was defined as a lack of donor cell 
engraftment by 28 days post-SCT and graft rejection 
as the loss of donor cells following engraftment with or 
without return to host hematopoiesis. Chimerism was 
assessed by FISH for sex mismatched transplants, or 
by variable tandem repeats (VTNR) for the same sex, 
while from January 2004 onwards, it was assessed by 
short tandem repeats (STR). 
OS and event-free survival (EFS) were obtained by 
the Kaplan-Meier method. The significance limit for P 
values was set at .05 in all tests. The χ2 test was used 
to compare frequencies. Death from any cause, relapse, 
graft failure and secondary malignancy were considered 
events for EFS. Outcomes were analyzed from the time 
of the patient’s stem cell infusion (day 0) until the first 
subsequent event or, for event-free patients, the time of 
the last follow-up.
RESULTS
Twelve (85.7%) patients engrafted; the median time to 
engraftment was 18 days (range, 11-32 days) for neu-
trophils and 28 days (range, 17-46 days) for platelets. 
Chimerism studies at the last contact were available for 
6 patients and all had complete donor chimerism. Five 
patients (35.71%) developed grade II acute GVHD 
which responded to treatment. Chronic GVHD of the 
liver and skin was seen in two patients, both respond-
ed to treatment with steroids and mycophenolate. No 
veno-occlusive disease (VOD), hemorrhagic cystitis or 
skin toxicity with etopside were observed. CMV infec-
tion developed in three patients and resolved with gan-
cyclovir therapy.
Three patients relapsed after complete engraft-
ment at a median of 99 days post-transplant (range, 
55-110 days) two patients had RC and monosomy 7 
and one had RAEB with complex cytogenetics. These 
patients died shortly after relapse secondary to disease 
progression. Four patients (28.57%) died at a median 
of 6 months post-transplant (range, 2-41 months). 
Causes of death were graft failure in two patients, and 
septic shock secondary to immune-suppressive thera-
py for chronic GVHD in two patients. Nine patients 
achieved CR and seven patients remain alive. At a me-
dian follow-up of 3 years (range 2-14 years) the OS 
and EFS was 57% (95%CI, 0.28-0.78) (Figures 1a, b). 
Cumulative EFS at 10 years was 43% (95% CI, 0.14-
0.70). Univariate analysis showed that patients younger 
than 5 years had a better survival (P=.001). However, 
neither the MDS subtype (P=.530) nor the presence of 
monosomy 7 (P=.592) had an impact on the EFS. No 
Figure 1. Kaplan-meier plot for (a) overall survival and (b) event-free survival, 3-year OS 
and efS; 0.571±0.132 (95%Ci: 0.28-0.7857%).
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cases of secondary malignancy were noted at median 
follow-up of 8 years (range, 2-14 years).
DISCUSSION
 Allogeneic SCT currently offers the best chance of cure 
and long-term survival for children with MDS.14-16 In 
this article we report the outcome of pediatric patients 
with MDS treated with allogeneic SCT at a single in-
stitution. To study a more homogeneous cohort of pa-
tients, and in compliance with the recent WHO classi-
fication, we excluded patients with JMML and second-
ary MDS from this analysis.
All patients received myeloablative conditioning 
regimens, which for most patients was BU/CY/VP16. 
Bu/Cy regimen alone or in combination with other 
agents provided an effective alternative to Cy/TBI in 
patients with AML and myelodyplasia.20,21 TBI-based 
regimens tend to be associated with an increased in-
cidence of NRM, acute GVHD, and growth failure.15 
The safety profile of etoposide as part of the condition-
ing regimen has been widely explored in adult stud-
ies.20 In children, however, few studies have addressed 
the use of high-dose etoposide (40-60 mg/kg) in com-
bination with other agents in the preparative regimens 
with lower dose of BU/CY. Although these studies 
showed that etoposide was fairly well tolerated, the 
investigators failed to show a clear advantage to using 
etoposide in AML patients.21,22 In this series, standard 
doses of Bu/Cy were used in addition to low dose of 
etoposide (30 mg/kg). The addition of etoposide was 
not associated with any unusual toxicity or delayed 
engraftment and there was no increased incidence of 
VOD or GVHD, and quite notable was the absence 
of skin toxicity. While we can conclude that the com-
bination of Bu/Cy with a lower dose of etoposide is a 
safe and effective myeloablative regimen for MDS, the 
small sample size of our study and the inability to con-
duct comparative analysis with published data due to 
heterogeneity of conditioning regimens used in these 
studies precludes validation of this observation.
Secondary malignancies, particularly acute leuke-
mia, are potential late effects of etoposide. TBI-based 
regimens also increase the risk of secondary malig-
nancy, including solid tumors. This issue was not ad-
dressed in many of the previously published series, but 
it should be considered when choosing the prepara-
tive regimen. In our study, with median follow up of 
6 years, no secondary malignancy was noted, although 
longer term follow-up is probably necessary, since the 
median time to development of epipodophyllotoxins 
related t-AML is short. It is likely that at least that risk 
may have been avoided.
The overall rate of EFS for MDS patients has ranged 
between 15% and 58% with relapse rates of 14% to 26%, 
and NRM of 40%. The limitation of these studies lies 
in the inclusion of patients with JMML and t-AML.11-
15 With an EFS of 57% and non-relapse mortality 
(NRM) of 28.6%, our results compare favorably with 
these reported studies. Recently Munoz et al23 reported 
the experience of the Spanish Working Party for Blood 
and Marrow Transplantation in Children (GETMON) 
with the use of allogeneic SCT from matched related 
donors, unrelated donors and cord blood in 24 patients 
with MDS applying the new WHO classification. The 
estimated EFS for all patients at 5 years was 38%. The 
estimated EFS at 5 years for patients in the MRD group 
was 48% versus 25% for the patients in the MUD/
UCB groups. The 5-year cumulative incidence of trans-
plant-related mortality (TRM) in the MRD group was 
33% versus 50% in the MUD/UCB groups (P=.05). 
Our study showed a similar EFS, and less incidence of 
NRM and GVHD. This could be explained by the con-
ditioning regimen used in this study. Contrary to what 
was reported by Parikh et al and Munoz et al19,23our 
study showed that age may have an impact on EFS with 
older patients doing better. Monosomy 7 did not influ-
ence the outcome in our series, similar to the experience 
of several recent studies.17,19,23 
Donor type has been considered as a major factor 
influencing outcome following allogeneic SCT. Studies 
specifically addressing the role of SCT in children with 
MDS have indicated a probability of EFS of about 50% 
following transplant with an HLA-matched family do-
nor,15,23 the same as obtained in our series. The use of 
unrelated BM donors was associated with a higher in-
cidence of acute and chronic GVHD, a higher TRM, 
and EFS probability of around 29%.22,24 Parikh et al19 
recently reported encouraging data regarding the use 
of UCB as a stem cell source for children with primary 
and secondary MDS. This study showed 3-year cumu-
lative survival of 60%, with a lower incidence of acute 
and chronic GVHD.
Relapse has been a major contributor to mortal-
ity in pediatric patients, with a statistically significant 
higher relapse rate in RAEB and RAEB-t cases as com-
pared with RC. Our study is similar to other studies 
that showed no correlation between relapse rate and 
MDS-subtype. In addition to graft failure, infections 
secondary to immunosuppression from GVHD and its 
therapy were a major cause of NRM in our patients, 
as shown in other series.15,19,23 Overall, quality of life 
for most patients was excellent with all but 1 of the 7 
surviving patients having a performance score of greater 
than or equal to 90%. 
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In conclusion, children with MDS may achieve en-
couraging OS and EFS following allogeneic SCT. The 
presence of monosomy 7 did not adversely affect the out-
come after transplantation. Graft failure and relapse were 
the main causes of treatment failure. However, methods 
to further improve outcome in patients with MDS un-
dergoing allogeneic transplantation are needed to de-
crease the relapse rate. This could be achieved through 
serial post SCT analysis of chimerism to detect the de-
velopment of mixed chimerism, which is a predictor of 
poor outcome, and the use of preemptive immunother-
apy with donor lymphocyte infusions or discontinuation 
of the immunosuppressive therapy.25,26 Tailoring the con-
dition regimens to reduce toxicity, while maintaining effi-
cacy, is definitely beneficial to this group of patients. The 
outcomes are best in younger patients, and transplant is 
thus recommended early in the course of the disease. 
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